Raynovent Announces Approval of Investigational New Drug (IND) Application of Category 1 Drug ZSP0678 for a New Indication

Previous:Breakthrough! China’s First Single-Agent 3CL Inhibitor, Leiretavir Tablets, Granted Conditional Approval

Next:Dr. Chen Xiaoxin, Vice President of Raynovent was Invited to Attend CHBD Year-end Party - Shenzhen Station.